Loading clinical trials...

Internet-Behavioral Cough Suppression Therapy | Clinical Trials | Clareo Health

COMPLETEDNA

Internet-Behavioral Cough Suppression Therapy

NCT05770401•University of Montana

Summary

The goal of this randomized, placebo-controlled, clinical trial is to develop and test the efficacy of an Internet-based behavioral intervention for refractory chronic cough. The main questions it aims to answer are: * What are the best recruitment pathways to find people living with refractory chronic cough in Montana? * Is Internet-Behavioral Cough Suppression Therapy (iBCST) efficacious? * Do iBCST participants find it satisfactory? * Is using Hyfe research app to monitor cough frequency feasible in rural areas? Participants will complete iBCST or a placebo treatment virtually. Some participants will take part in qualitative interviews and use Hyfe research app for ambulatory cough frequency monitoring.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•No barriers to using a computer or smartphone (e.g., no significant fine motor or visual problems).
•Internet and e-mail access and the ability to use it.
•Suffering from a cough lasting at least eight weeks that is:
•Largely unproductive (cough up no more than a few teaspoons worth of clear or white sputum or mucus in a 24-hour period).
•Report of cough triggered by identifiable stimuli including and not limited to any combination of the following: cold air, talking, laughing, taking a deep breath, exercise, crumbly foods, strong smells or odors, fumes from paint or cleaning sprays.
•Often preceded by the sensation of an urge-to-cough (e.g., tickle or itch) at the level of the throat.
•Self-report of receiving the following assessments for current cough symptoms with unremarkable results:
•Physical evaluation by at least one physician.
•Chest x-ray.
•Willingness to avoid other potential cough treatments during the course of the study (or alert study personnel if alternative treatment is implemented out of necessity).

Exclusion Criteria

•Current smoker of any substance.
•Diagnosis of any of the following:
•Respiratory disease (e.g., chronic obstructive pulmonary disease, asthma)
•Neurogenic disease (e.g., Parkinson's disease, cerebrovascular disease)
•Head and neck cancer
•Self-report of difficulty swallowing since having chronic cough
•Use of the following medication:
•Angiotensin-converting enzyme inhibitor (ACE-I) in the past four weeks: benzapril (Lotensin), Captopril (Capoten), Enalapril/Enalaprilat (Vasotec oral and injectable), Fosinopril (Monopril), Lisinopril (Zestril and Prinivil), Moexipril (Univasc), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), and Trandolapril (Mavik).
•Use of a neuromodulator medication in the past 48 hours: Neurontin (Gabapentin) and amitriptyline.
•Individuals with dysphonia (abnormal voice; either self-reported or perceived by study personnel during enrollment interview) will be excluded unless they have had a normal laryngoscopy (endoscopic assessment of the larynx) by an otolaryngologist (ENT) within the past year specifically for their cough.

Locations (1)

University of Montana

Missoula, Montana, United States

Key Dates

Start Date

July 1, 2023

Primary Completion Date

July 1, 2024

Completion Date

July 1, 2024

Last Updated

June 5, 2025

Enrollment

ACTUAL participants

Conditions

CoughChronic Disease

Interventions

Internet-Behavioral Cough Suppression Therapy

BEHAVIORAL

Sham Treatment

BEHAVIORAL

Click & Pick Study

NCT07422922

Chronic Disease

View study

RECRUITING

Laryngeal Cryotherapy for Refractory Neurogenic Cough

NCT05665244

Upper-Airway Cough Syndrome

View study

RECRUITINGNA

Validation of the C-mo System - Cough Monitoring

NCT05989698

Cough

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Internet-Behavioral Cough Suppression Therapy

Inclusion Criteria

Exclusion Criteria

Click & Pick Study

Laryngeal Cryotherapy for Refractory Neurogenic Cough

Validation of the C-mo System - Cough Monitoring

Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial

Inhaled Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Post-Infectious Cough: A Single-Center Randomized Controlled Clinical Trial

Barriers to Vegetarian Diets